HIV Mutation Detail Information

> K10I Search Result

Mutation Information

Mutation Site	K10I
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Relevant Drug	PIs
Country	New Jersey

Literature Information

PubMed PMID	17620130
Disease	HIV infection/AIDS
Published Year	2007
Journal	AIDS research and therapy
Title	Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.
Author	Malhotra A,Gaur S,Whitley-Williams P,Loomis C,Petrova A
Evidence	A few non-classified mutations in the HIV-1 genome such as F 214L (n = 1, 3.3%), I64V (n = 3, 10.0%), K10I (n = 3, 10.0%), R21I (n = 1, 3.3%), S68G (n = 2, 6.6%), and L214F (n = 1, 3.3%) were also observed in the children treated with PI medications. Moreover, the HIV-1 isolates from the NNRTI and PI naive children showed NNRTI (n = 4/20, 20.0%) and secondary (class III-IV) PI associated mutations (n = 6/13, 46.1%).

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation